OnKure Therapeutics, Inc. (OKUR)
| Market Cap | 118.65M +236.0% |
| Revenue (ttm) | n/a |
| Net Income | -58.71M |
| EPS | -2.58 |
| Shares Out | 40.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 149,716 |
| Open | 2.960 |
| Previous Close | 2.940 |
| Day's Range | 2.880 - 3.050 |
| 52-Week Range | 2.230 - 5.380 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 15.50 (+429.01%) |
| Est. Earnings | Nov 5, 2026 |
About OKUR
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for OKUR stock is "Strong Buy." The 12-month stock price target is $15.5, which is an increase of 429.01% from the latest price.
News
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today an...
OnKure Therapeutics price target lowered to $14 from $30 at Oppenheimer
Oppenheimer lowered the firm’s price target on OnKure Therapeutics (OKUR) to $14 from $30 and keeps an Outperform rating on the shares. The firm notes the company gave its quarterly…
OnKure Therapeutics reports Q2 EPS (31c), consensus (54c)
“Following our strategic transformation earlier this year, we continue to advance our next-generation PI3Kalpha pan-mutant selective inhibitor pipeline, which we believe represents the most compelling...
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027
OnKure Therapeutics Slides: Corporate presentation
OnKure Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
OnKure Therapeutics Quarterly report: Q2 2026
OnKure Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
OnKure Therapeutics Earnings release: Q2 2026
OnKure Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
OnKure Therapeutics price target lowered to $21 from $27 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns lowered the firm’s price target on OnKure Therapeutics (OKUR) to $21 from $27 and keeps a Buy rating on the shares. Preclinical data for OKI-345…
OnKure Therapeutics Transcript: KOL event
The event highlighted the scientific rationale and preclinical performance of pan-mutant selective PI3Kα inhibitors, emphasizing allosteric targeting for superior selectivity and safety. Key opinion leaders discussed the clinical need, resistance mechanisms, and strategic plans for advancing OKI-345 and OKI-355 into trials, with a focus on minimizing side effects and maximizing efficacy.
OnKure Therapeutics Slides: KOL event
OnKure Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 15, 2026.
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced ...
OnKure Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and an equity plan amendment. All proposals passed, with directors elected through 2029 and KPMG confirmed as auditor. No shareholder questions were raised.
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded OnKure Therapeutics (OKUR) to Hold from Buy after the company recently announced the discontinuation of their OKI-219, being developed for metastatic/advanced breast cancer, a...
OnKure Therapeutics Reports First Quarter 2026 Financial Results
-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company's pipeline i...
OnKure Therapeutics Quarterly report: Q1 2026
OnKure Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
OnKure Therapeutics Earnings release: Q1 2026
OnKure Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
OnKure Therapeutics files to sell 36.14M shares of Class A common for holders
16:05 EDT OnKure Therapeutics (OKUR) files to sell 36.14M shares of Class A common for holders
OnKure Therapeutics Registration statement: Registration filing
OnKure Therapeutics filed a registration statement on April 24, 2026, providing details about a securities offering with the SEC.
OnKure Therapeutics Slides: Corporate presentation
OnKure Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 24, 2026.
OnKure Therapeutics Proxy statement: Proxy filing
OnKure Therapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
OnKure Therapeutics Proxy statement: Proxy filing
OnKure Therapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
OnKure Therapeutics to sell 26.713M shares at $4.15 in private placement
OnKure Therapeutics (OKUR) announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proc...
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and...
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on OnKure Therapeutics (OKUR) to $27 from $34 and keeps a Buy rating on the shares post the Q4 report. The firm dropped…
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
“We are pleased with the continued progress across our PI3Kalpha-focused pipeline, including the steady execution of the PIKture-01 trial of OKI-219. We look forward to sharing updated data from this…